title: The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
abstract: OBJECTIVE
  To investigate the effect of the serotonin receptor agonist dexfenfluramine on eating habits and weight loss in ambulatory, android type, moderately obese patients with an overconsumption of snacks.
  
  
  METHODS
  9 week, randomized, double-blind treatment with either dexfenfluramine (30 mg/day) or placebo, without dietary intervention.
  
  
  METHODS
  Outpatient clinics of four University Hospitals in The Netherlands.
  
  
  METHODS
  112 healthy obese subjects, body mass index 28-35 kg/m2, waist-to-hip ratio > or = 1.0 for men and > or = 0.8 for women, consuming more than five snacks containing in total more than 500 kcal/day and/or more than 25% of total calorie intake in the form of snacks.
  
  
  METHODS
  Changes in macronutrient composition of the diet, food intake (total, at principal meals and in between meals in the form of snacks) and weight loss.
  
  
  RESULTS
  104 subjects were included for efficacy analysis. In both the dexfenfluramine group (n = 51) and the placebo group (n = 53) the total energy intake decreased. The decrease during main meals was significantly greater in the dexfenfluramine group for all parameters tested except for simple carbohydrates. In between meals the decrease in intake was significantly greater in the dexfenfluramine group for total energy intake (P < 0.05) and intake in unsaturated fat (P < 0.05). The reported reduction in total food intake in the dexfenfluramine group was similarly due to reductions in carbohydrate and fat intake. No weight loss was seen in the placebo group. The treated group lost 3.1 +/- 0.2 kg (P < 0.01).
  
  
  CONCLUSIONS
  Dexfenfluramine effectively reduces the intake of carbohydrates as well as fat in ambulatory, non diet restricted android obese subjects by reducing food intake during and in between main meals.
authors.affiliation: Department of Endocrinology, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: M L
authors.initials: ML
authors.lastname: Drent
authors.forename: P M
authors.initials: PM
authors.lastname: Zelissen
authors.forename: H P
authors.initials: HP
authors.lastname: Koppeschaar
authors.forename: A C
authors.initials: AC
authors.lastname: Nieuwenhuyzen Kruseman
authors.forename: J A
authors.initials: JA
authors.lastname: Lutterman
authors.forename: E A
authors.initials: EA
authors.lastname: van der Veen
mesh_terms: D000328:Adult; D000428:Alcohol Drinking; D000553:Ambulatory Care / Q000592:standards*; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004311:Double-Blind Method; D004435:Eating / Q000187:drug effects / Q000502:physiology; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D009765:Obesity / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology
chemical_list: D004040:Dietary Carbohydrates; D005277:Fenfluramine